IN2014CN04742A - - Google Patents

Info

Publication number
IN2014CN04742A
IN2014CN04742A IN4742CHN2014A IN2014CN04742A IN 2014CN04742 A IN2014CN04742 A IN 2014CN04742A IN 4742CHN2014 A IN4742CHN2014 A IN 4742CHN2014A IN 2014CN04742 A IN2014CN04742 A IN 2014CN04742A
Authority
IN
India
Prior art keywords
domain
polypeptides
influenza hemagglutinin
influenza
stem segment
Prior art date
Application number
Other languages
English (en)
Inventor
Jan Wilem Meijberg
Antonietta Impagliazzo
Ronald Vogels
Robert Heinz Edward Friesen
Philippe Alard
Stefan Loverix
Katarina Radoševic
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of IN2014CN04742A publication Critical patent/IN2014CN04742A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN4742CHN2014 2011-11-28 2012-11-27 IN2014CN04742A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161564198P 2011-11-28 2011-11-28
US201161564086P 2011-11-28 2011-11-28
EP11191009 2011-11-28
EP11191003 2011-11-28
EP12166268 2012-05-01
US201261720281P 2012-10-30 2012-10-30
PCT/EP2012/073706 WO2013079473A1 (en) 2011-11-28 2012-11-27 Influenza virus vaccines and uses thereof

Publications (1)

Publication Number Publication Date
IN2014CN04742A true IN2014CN04742A (ja) 2015-09-18

Family

ID=48534691

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4742CHN2014 IN2014CN04742A (ja) 2011-11-28 2012-11-27

Country Status (20)

Country Link
US (3) US9452211B2 (ja)
EP (2) EP3566714A1 (ja)
JP (1) JP6294828B2 (ja)
KR (1) KR101983989B1 (ja)
CN (1) CN104066446B (ja)
AR (1) AR089005A1 (ja)
AU (1) AU2012343981B2 (ja)
BR (1) BR112014012681A8 (ja)
CA (1) CA2857087C (ja)
EA (1) EA033386B1 (ja)
HK (1) HK1199211A1 (ja)
IL (1) IL232780A (ja)
IN (1) IN2014CN04742A (ja)
MX (1) MX357009B (ja)
MY (1) MY170927A (ja)
PH (1) PH12014501118B1 (ja)
SG (1) SG11201402633UA (ja)
TW (1) TWI618715B (ja)
WO (1) WO2013079473A1 (ja)
ZA (1) ZA201404797B (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP3900740A1 (en) 2010-03-30 2021-10-27 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
EA201490659A1 (ru) 2011-09-20 2014-11-28 Маунт Синай Скул Оф Медсин Вакцины против вируса гриппа и их применения
IN2014CN04742A (ja) 2011-11-28 2015-09-18 Crucell Holland Bv
JP2015519348A (ja) * 2012-05-23 2015-07-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ インフルエンザワクチン構築物
CN108641002A (zh) 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3004142B1 (en) * 2013-05-30 2020-09-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US9393297B2 (en) * 2013-08-03 2016-07-19 Avatar Medical, Llc Influenza hemagglutinin proteins and methods of use thereof
EP3137487B1 (en) 2014-05-01 2021-03-03 Indian Institute of Science Polypeptides for generating anti-influenza antibodies and uses thereof
JP2017521063A (ja) 2014-06-26 2017-08-03 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 微小管結合タンパク質タウに特異的に結合する抗体及び抗原結合断片
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
BR112017000257A2 (pt) * 2014-07-10 2017-10-31 Janssen Vaccines & Prevention Bv vacinas contra o vírus da gripe e usos das mesmas
IL249704B (en) * 2014-07-10 2021-03-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and their uses
BR112016030577A8 (pt) * 2014-07-10 2021-07-20 Janssen Vaccines & Prevention Bv polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
CA2985402A1 (en) * 2015-05-11 2016-11-17 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
JP6975709B2 (ja) 2015-09-02 2021-12-01 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化したウイルスクラスｉ融合タンパク質
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
SG11201901790YA (en) * 2016-09-02 2019-03-28 The Usa As Represented By The Secretary Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
WO2018053178A1 (en) * 2016-09-16 2018-03-22 Vaccitech, Inc. Compositions and methods for vaccination against influenza
EP3939604A3 (en) * 2016-10-21 2022-06-22 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
EP3713600A4 (en) * 2017-11-22 2021-08-11 Her Majesty The Queen In Right of Canada as represented by The Minister of Health SYNTHETIC HEMAGGLUTININ AS A UNIVERSAL VACCINE AGAINST INFECTION BY TYPE B INFLUENZA VIRUSES (IBV)
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
SG11202006399VA (en) * 2018-01-23 2020-08-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
AU2020263900A1 (en) * 2019-04-25 2021-10-14 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
WO2021043869A1 (en) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2021074286A2 (en) * 2019-10-15 2021-04-22 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2022051327A1 (en) * 2020-09-02 2022-03-10 St. Jude Children's Research Hospital, Inc. Hemagglutinin modifications for improved influenza vaccine production
BR112023004123A2 (pt) 2020-09-07 2023-04-04 Intervet Int Bv Vacina de haste da ha para alvos positivos de anticorpos de ha
WO2023274860A1 (en) * 2021-06-28 2023-01-05 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2024038382A1 (en) * 2022-08-16 2024-02-22 Seqirus Inc. Modified influenza viruses
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN116947982B (zh) * 2023-07-12 2024-05-14 吉林大学 三条优势表位肽序列及其在流感病毒疫苗的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6248780B1 (en) 1998-10-01 2001-06-19 Duquesne University Of The Holy Ghost Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
AU9434801A (en) 2000-08-10 2002-02-18 Crucell Holland Bv Gene delivery vectors with cell type specificity for primary human chondrocytes
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
EP1497438B1 (en) 2002-04-25 2009-10-28 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
CA2478508C (en) 2002-04-25 2013-07-02 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US20050221493A1 (en) 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
BRPI0414670A (pt) 2003-10-02 2006-11-21 Crucell Holland Bv método para preparar uma célula, célula, métodos para fornecer uma célula e para gerar uma batelada de adenovìrus recombinante, molécula recombinante, conjunto de pelo menos duas moléculas de ácido nucleico, e, sistema de empacotamento
BRPI0518933A2 (pt) 2004-11-16 2008-12-16 Crucell Holland B V E Aeras Gl adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
AU2007293662B2 (en) * 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
US9051359B2 (en) * 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
CN102448986B (zh) 2009-05-11 2015-11-25 克鲁塞尔荷兰公司 能中和流感病毒h3n2的人结合分子及其应用
EP3900740A1 (en) * 2010-03-30 2021-10-27 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
AU2011310838B2 (en) 2010-09-27 2015-11-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CN103906763B (zh) 2011-07-14 2016-10-12 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
IN2014CN04742A (ja) 2011-11-28 2015-09-18 Crucell Holland Bv
US20130236494A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
MY170407A (en) 2012-03-08 2019-07-27 Crucell Holland Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
CN104662041A (zh) 2012-09-27 2015-05-27 克鲁塞尔荷兰公司 能够结合到并且中和b型肝炎病毒的人类结合分子及其用途
EP3004142B1 (en) 2013-05-30 2020-09-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
BR112017000257A2 (pt) 2014-07-10 2017-10-31 Janssen Vaccines & Prevention Bv vacinas contra o vírus da gripe e usos das mesmas
BR112016030577A8 (pt) 2014-07-10 2021-07-20 Janssen Vaccines & Prevention Bv polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes

Also Published As

Publication number Publication date
MX2014006396A (es) 2014-07-22
WO2013079473A1 (en) 2013-06-06
CN104066446A (zh) 2014-09-24
EA033386B1 (ru) 2019-10-31
IL232780A0 (en) 2014-07-31
KR20140099515A (ko) 2014-08-12
BR112014012681A8 (pt) 2017-06-20
PH12014501118A1 (en) 2014-08-04
AR089005A1 (es) 2014-07-23
US20160355553A1 (en) 2016-12-08
CA2857087C (en) 2021-05-25
TWI618715B (zh) 2018-03-21
IL232780A (en) 2017-09-28
ZA201404797B (en) 2022-03-30
NZ625973A (en) 2016-09-30
BR112014012681A2 (pt) 2017-06-13
EA201491051A1 (ru) 2015-04-30
MX357009B (es) 2018-06-22
MY170927A (en) 2019-09-19
JP6294828B2 (ja) 2018-03-14
AU2012343981A1 (en) 2014-07-10
HK1199211A1 (en) 2015-06-26
EP2785372A1 (en) 2014-10-08
US9452211B2 (en) 2016-09-27
US20140357845A1 (en) 2014-12-04
AU2012343981B2 (en) 2017-09-07
PH12014501118B1 (en) 2014-08-04
EP2785372B1 (en) 2019-06-19
SG11201402633UA (en) 2014-09-26
KR101983989B1 (ko) 2019-05-31
CN104066446B (zh) 2017-10-03
US20160362455A1 (en) 2016-12-15
JP2015502353A (ja) 2015-01-22
CA2857087A1 (en) 2013-06-06
EP3566714A1 (en) 2019-11-13
TW201329101A (zh) 2013-07-16
US9969778B2 (en) 2018-05-15

Similar Documents

Publication Publication Date Title
IN2014CN04742A (ja)
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
PH12015502612A1 (en) Influenza virus vaccines and uses thereof
IN2014CN00953A (ja)
EA201171220A1 (ru) Мутанты fgf21 и их применение
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
EP3936141A3 (en) Anti-senescence compounds and uses thereof
MX371403B (es) Moleculas de andamiaje a base de fibronectina estabilizada.
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
MX350445B (es) Analogos del factor b del complemento y sus usos.
NI201700156A (es) Péptidos lipidados resistentes a proteasas
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
SG10201908920QA (en) Influenza virus vaccines and uses thereof
EA201590431A1 (ru) Пшеница с новыми аллелями rht-b1
WO2015171395A3 (en) Degradation resistant peptide based biosensors
WO2010111597A3 (en) Immunodominant compositions and methods of use therefor
CU20140061A7 (es) Vacunas contra virus influenza y sus usos
BG111616A (bg) Екстракти от охлюв helix aspersa
MY155338A (en) Novel insulin derivatives having an extremely delayed time-action profile